Osteoclast-Derived Matrix Metalloproteinase-9 Directly Affects Angiogenesis in the Prostate Tumor–Bone Microenvironment

In human prostate to bone metastases and in a novel rodent model that recapitulates prostate tumor–induced osteolytic and osteogenic responses, we found that osteoclasts are a major source of the proteinase, matrix metalloproteinase (MMP)-9. Because MMPs are important mediators of tumor-host communication, we tested the effect of host-derived MMP-9 on prostate tumor progression in the bone. To this end, immunocompromised mice that were wild-type or null for MMP-9 received transplants of osteolytic/osteogenic-inducing prostate adenocarcinoma tumor tissue to the calvaria. Surprisingly, we found that that host MMP-9 significantly contributed to prostate tumor growth without affecting prostate tumor–induced osteolytic or osteogenic change as determined by microcomputed tomography, microsingle-photon emission computed tomography, and histomorphometry. Subsequent studies aimed at delineating the mechanism of MMP-9 action on tumor growth focused on angiogenesis because MMP-9 and osteoclasts have been implicated in this process. We observed (a) significantly fewer and smaller blood vessels in the MMP-9 null group by CD-31 immunohistochemistry; (b) MMP-9 null osteoclasts had significantly lower levels of bioavailable vascular endothelial growth factor-A164; and (c) using an aorta sprouting assay, conditioned media derived from wild-type osteoclasts was significantly more angiogenic than conditioned media derived from MMP-9 null osteoclasts. In conclusion, these studies show that osteoclast-derived MMP-9 affects prostate tumor growth in the bone microenvironment by contributing to angiogenesis without altering prostate tumor–induced osteolytic or osteogenic changes. Mol Cancer Res; 8(4); 459–70. ©2010 AACR.

[1]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[2]  E. van Marck,et al.  Zoledronic Acid Treatment of 5T2MM‐Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  G. Roodman,et al.  Perspective on the Osteoclast , 2007 .

[4]  J. Martignetti,et al.  Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. , 2007, Human molecular genetics.

[5]  L. Matrisian,et al.  Matrix metalloproteinases in tumor-host cell communication. , 2002, Differentiation; research in biological diversity.

[6]  T. Wilson,et al.  Cathepsin G–Mediated Activation of Pro–Matrix Metalloproteinase 9 at the Tumor-Bone Interface Promotes Transforming Growth Factor-β Signaling and Bone Destruction , 2009, Molecular Cancer Research.

[7]  P. Watson,et al.  A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. , 2001, European journal of cancer.

[8]  L. Devy,et al.  Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis , 2002, Biological Procedures Online.

[9]  T. Plesner,et al.  A physical mechanism for coupling bone resorption and formation in adult human bone. , 2008, The American journal of pathology.

[10]  M. Endo,et al.  Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. , 2005, AJR. American journal of roentgenology.

[11]  J. Ward,et al.  MT1-MMP-Deficient Mice Develop Dwarfism, Osteopenia, Arthritis, and Connective Tissue Disease due to Inadequate Collagen Turnover , 1999, Cell.

[12]  M. Cher,et al.  Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate cancer bone metastasis , 2007, Clinical & Experimental Metastasis.

[13]  R. Fridman,et al.  Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. , 2002, Journal of the National Cancer Institute.

[14]  Xiyun Deng,et al.  CXCL12/CXCR4 signaling activates Akt‐1 and MMP‐9 expression in prostate cancer cells: The role of bone microenvironment‐associated CXCL12 , 2006, The Prostate.

[15]  C. Barnstable,et al.  Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix remodeling in the bone. , 2004, Biochemical and biophysical research communications.

[16]  Gabriele Bergers,et al.  MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes , 1998, Cell.

[17]  S. Rafii,et al.  Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.

[18]  T. Shirai,et al.  Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) in the rat prostate and induction of invasive carcinomas by subsequent treatment with testosterone propionate. , 1999, Cancer letters.

[19]  D. Albertson,et al.  Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability , 2005, Nature.

[20]  I. Fidler,et al.  Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. , 2007, Neoplasia.

[21]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[22]  K. Moriyama,et al.  Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and Osteopontin , 2007, Clinical Cancer Research.

[23]  G. Mundy.  Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[24]  G. Mundy,et al.  A murine model of myeloma that allows genetic manipulation of the host microenvironment , 2009, Disease Models & Mechanisms.

[25]  L. Matrisian,et al.  A Protective Role for Matrix Metalloproteinase-3 in Squamous Cell Carcinoma , 2004, Cancer Research.

[26]  Tomoyuki Shirai,et al.  MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. , 2005, Cancer cell.

[27]  L. Filgueira,et al.  Fluorescence-based Staining for Tartrate-resistant Acidic Phosphatase (TRAP) in Osteoclasts Combined with Other Fluorescent Dyes and Protocols , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[28]  L. Matrisian,et al.  Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. , 2009, Cancer research.

[29]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[30]  Nils Brünner,et al.  Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  S. Itohara,et al.  A Crucial Role for Matrix Metalloproteinase 2 in Osteocytic Canalicular Formation and Bone Metabolism* , 2006, Journal of Biological Chemistry.

[32]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[33]  Craig Murdoch,et al.  Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. , 2008, Neoplasia.

[34]  H. Birkedal‐Hansen,et al.  The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone , 2005, Journal of Cell Science.

[35]  M. Cher,et al.  Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP‐12 dependent manner , 2008, International journal of cancer.

[36]  E. Keller,et al.  Prostate cancer bone metastases promote both osteolytic and osteoblastic activity , 2004, Journal of cellular biochemistry.

[37]  Thiennu H. Vu,et al.  Matrix Metalloproteinase 9 and Vascular Endothelial Growth Factor Are Essential for Osteoclast Recruitment into Developing Long Bones , 2000, The Journal of cell biology.

[38]  V. Stewart,et al.  RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement , 1992, Cell.

[39]  Heath B Acuff,et al.  Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. , 2006, Cancer research.

[40]  M. Bernardo,et al.  Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism‐based selective gelatinase inhibitor , 2006, International journal of cancer.

[41]  J. Quigley,et al.  Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis , 2007, Proceedings of the National Academy of Sciences.